ClinicalTrials.gg
Status unknownNCT05451199Updated Apr 18, 2023

A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis

A Phase 1 interventional study of ICP-488 and Placebo in Psoriasis, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Status unknown at 7 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
96th of 182
154 · median 171
Started
2022
with 14 others
Phase 1
37 of 206
5 open now
Registered
86th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 96th largest by planned enrollment of the 182 interventional ones that give a count, is one of 15 that started in 2022, is one of 37 in phase 1, and was the 86th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients With Psoriasis

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed , and was able to communicate well with the investigator and can complete the study according to the study requirement.
  2. (BMI) between 18-26 kg/m2, the weight of male subject should not be less than 50 kg, and the weight of female subject should not be less than 45 kg.
  3. The results of laboratory tests during the screening period are within the normal reference values of the population or study site;Or the results were slightly off but within acceptable limits, and the investigator evaluated that they were not .
  4. Fertility status: Female subjects who are infertile (i.e. physically unable to conceive, including or surgically infertile women);Male subjects and their partners must agree to use effective for the entire study period and for 28 days after the last medication or for five half-lives, and male subjects shall not donate sperm during this period.
  5. Male or female subjects aged ≥ 18 years and ≤ 65 years;
  6. Diagnosis of plaque psoriasis;
  7. All of the following 3 criteria are met at screening and randomization:

1)Psoriasis Area and Severity Index (PASI) ≥ 12; 2)Physician Global Assessment (PGA) ≥ 3; 3)Body surface area (BSA) affected by psoriasis ≥ 10%.

  1. The subject is a candidate to receive systemic therapy and/or phototherapy.

Exclusion criteria

Exclusion Criteria:

  1. Unable to follow the study protocol requirements.
  2. Evidence or history of disease, or evidence or history of allergic disease.
  3. Subjects with clinically significant gastrointestinal dysfunction that may affect drug intake, transport or absorption.
  4. Acute disease state within 14 days before administration.
  5. Currently or within 6 months prior to administration experiencing a severe infection or having a long-term or recurrent infection disease
  6. Subjects and/or first-degree relatives have a genetic immune deficiency.
  7. Major trauma or surgery within 3 months prior to the first administration.
  8. Previous medical history of tuberculosis; The presence of investigator-judged signs or symptoms of active tuberculosis and the chest imaging showed active pulmonary tuberculosis at screening ;T-spoT test (T-SPOT) was positive at screening.
  9. Urine drug test positive.
  10. Alcoholic
  11. Subjects who have used tobacco/cigarettes or tobacco/cigarette products within 3 months prior to the first administration.
  12. Subjects who donated more than 500 ml of blood (excluding plasma) within 56 days before the first dose, or planned to donate blood or blood components during the study period or within 1 month after the study finished.
  13. Use of any other study drug specified in the protocol within 30 days prior to initial administration or within 5 half-lives(refer to whichever is longer).
  14. Any traditional Chinese medicine (TCM) and over-the-counter (OTC) drugs, vitamins, systemic hormone therapy, or modulator therapy, hormone replacement therapy, and other food supplements or herbs were used 30 days before the first dose until follow-up visit.
  15. Consume any food or drink containing caffeine within 48 hours prior your first administration.
  16. Last use of stron , moderate and weak CYP1A2/ inhibitors or inducers less than 5 half-lives before the first dose of study drug, or planning to take medications, dietary supplements, or foods
  17. Diet or dietary treatment within 30 days prior to initial administration or have significant change in eating habits.
  18. Eat smoked charcoal fire foods (such as Carbon barbecue,etc) within 1 week prior to the study.
  19. Any positive showed in the lab result of syphilis specific antibody, antibody (HCV-Ab), surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or serological antibody (HIV-Ab) during screening.
  20. Received vaccination with , live attenuated vaccine or any live virus component is administered within 6 weeks prior to initial administration, or during the planned study period or within 8 weeks after the end of the study.
  21. Non-plaque forms of psoriasis.
  22. Drug-induced psoriasis.
  23. Are taking or require oral or injectable corticosteroids for any medical condition.
  24. Clinically significant test results at the time of screening that, in the investigator's judgment, may cause unacceptable risk to the participant.
  25. History of active tuberculosis,active hepatitis B virus、active hepatitis C virus or Syphilis infection.
  26. Clinically severe, progressive, or uncontrolled disease at screening; Pregnant female subjects.
  27. breastfeeding female subjects.
  28. Other situations judged by the investigator to be unsuitable to join this trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    ICP-488

    Single ascending doses of ICP-488 tablet; Multiple ascending doses of ICP-488 tablet; Part3 Patients with Psoriasis:ICP-488 tablet.

    Drug: ICP-488

  • Placebo comparator
    Placebo

    Single ascending doses of placebo; Multiple ascending doses of placebo; Part3 Patients with Psoriasis of placebo.

    Drug: Placebo

Interventions

  • ICP-488 will be administered as tablet

  • DrugPlacebo

    Matching placebo will be administered as tablet

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events during treatment, and withdrawal from treatment due to adverse events

    Time frame: Single ascending dose: 1day;Multiple ascending dose: 28 days

Secondary outcomes

  1. Cmax

    Time frame: Single ascending dose: 1day;Multiple ascending dose: 28 days

  2. Psoriasis Area and Severity Index (PASI)

    Time frame: Day1,Day7,Day14,Day21,Day28,Day35,Day42,Day56

  3. Body Surface Area (BSA)

    Time frame: Day1,Day7,Day14,Day21,Day28,Day35,Day42,Day56

  4. Static Physician's Global Assessment (sPGA)

    Time frame: Day1,Day7,Day14,Day21,Day28,Day35,Day42,Day56

  5. Peak Pruritus Numerical Rating Scale (PP-NRS)

    Time frame: Day1-Day14, Day21, Day28, Day35, Day42, Day56

  6. Dermatology quality of life index (DLQI)

    Time frame: Day1,Day7,Day14,Day21,Day28,Day35,Day42,Day56

07

Study locations

2 of 7 sites recruiting
  • The Second Hospital of Anhui Meidcal University
    Hefei, Anhui 230601, China
    Not yet recruiting
    • Chunjun Yang · Contact
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Not yet recruiting
    • Guoqiang Zhang · Contact
  • Nanyang First People's Hospital
    Nanyang, Henan 473004, China
    Not yet recruiting
    • Rixin Chen · Contact
  • Shiyan Renmin Hospital
    Shiyan, Hubei 442000, China
    Recruiting
    • Zudong Meng · Contact
  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of medical Sciences, Peking Union Medical College
    Nanjing, Jiangsu 210000, China
    Recruiting
    • Qianjin Lu · Contact
  • Yanbian University Hospital
    Yanji, Jilin 133000, China
    Not yet recruiting
    • Zhehu Jin · Contact
  • Hangzhou First People's Hospital
    Hangzhou, Zheajing 310006, China
    Not yet recruiting
    • Liming Wu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Oct 2023, 15 months after the start.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 15 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2022
First posted
Jul 11, 2022
StartActual
Jul 29, 2022
Primary completionEst.
Oct 30, 2023
CompletionEst.
Dec 31, 2023
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05451199
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
Jul 29, 2022
Primary completion
Oct 30, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Apr 18, 2023

Study contacts

Lisa Zhao
Contact
Lisa.zhao@innocarepharma.com
+86 18233150939
Qianjin Lu
principal investigator · Hospital for Skin Diseases, Chinese Academy of medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ICP-488

Start the discussion